Chimeric antigen receptor (CAR) T cell therapy is used to treat multiple cancer types that are refractory to standard chemotherapy. Unfortunately, though initially effective, many patients receiving CAR T therapy relapse within a few months of receiving treatment. This may result from ineffective targeting of low antigen expressing malignant cells and/or the inability of CAR T cells to persist for a long period of time after infusion. A team led by Dr. Mark Kohler has designed novel bicistronic CAR T cell constructs that have demonstrated improved sensitivity to tumors with low levels of antigen and that persist longer in animal models compared to other CD22 CAR T cells. The inventors believe their improved CAR T cells will be effective against a number of blood cancers and solid tumors.
Download Summary Document Here:
http://cuamc.technologypublisher.com/files/sites/cu5685h_ncs_updated.pdf